More than 6.5 billion blood lipid-lowering drugs! Yellow Sea Pharmaceuticals is about to be approved.

Pharmaceutical Network September 1st, recently, Huanghai Pharmaceuticals according to the imitation of 4 categories of reported calcium reschuvastatin tablets (acceptance number CYHS1900180, CYHS1900181) registration status changed to "in approval", is expected to be approved in recent days and treated as reviewed.
is the first batch of calcium tablets collected, Milnenet data show that in 2019, China's public medical institutions terminal Ruishuvastatin sales of more than 6.5 billion yuan, down 3.52% YoY.
Reschuvastatin is a selective, competitive HMG-CoA reductase inhibitor, is currently one of the latest statins, because of its strong, fast and safe blood lipid-lowering characteristics, known as "super statin."
statin calcium tablets originally developed by AstraZenecon, the product named Canding, listed in the United States in 2003 and in China in 2006.
AstraZenece reported a marked decline in sales since the patent expired in 2016, with global sales of $1,278 million in 2019, down 10.8 percent from a year earlier, and global sales of $583 million from 2020H1, down 10 percent from a year earlier. In 2019, sales of Rishuvastatin at urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) reached more than 6.5 billion yuan, down 3.52% year-on-year, according to
meters of intranet data.
, AstraZeneta has a market share of 49.56 per cent, Lunanbet Pharmaceuticals 15.44 per cent and Jingxin Pharmaceuticals 14.12 per cent.
ruishuvastatin calcium tablets listed on the market application in the review enterprise Ruishuvastatin calcium tablets for the first collection of varieties.
At present, there are still a number of pharmaceutical companies layout of the product, 13 enterprises submitted a copy of the Rishuvastatin calcium tablets listed application in the review;
source: MiNet Database, NMPA.